Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer
- PMID: 9743058
- DOI: 10.1097/00007611-199809000-00010
Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer
Abstract
Objectives: We sought to determine the prevalence of hot flushes after neoadjuvant hormonal therapy.
Methods: Forty-three patients who received neoadjuvant hormonal therapy before radical prostatectomy were asked to complete a questionnaire regarding hot flushes.
Results: Complete information was available for 35 of the 43 patients. No hot flushes were noted in 20%; in 69%, hot flushes were noted during treatment but resolved after termination of treatment; and in 11%, hot flushes continued for at least 3 months after cessation of hormonal therapy. Analyzing the data with respect to duration of hormonal therapy showed that patients receiving neoadjuvant hormonal therapy for more than 4 months had the highest incidence of persistent hot flushes.
Conclusions: Hot flushes will be noted in 80% of patients who receive neoadjuvant hormonal therapy. In approximately 10%, hot flushes will continue for a significant period after hormonal therapy is terminated. Patients should be apprised of this potential side effect.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical